Nawah Scientific is a premier Contract Research Organization (CRO) and ISO 17025 accredited SME operating across the MENA region and the EU. As a Horizon Europe Associated Country partner, we bring full funding eligibility and a unique "Cloud Lab" infrastructure that processes over 1 million samples annually for clients in 30+ countries.
OUR VALUE PROPOSITION: We offer Health Consortiums a "One-Stop-Shop" for Analytical Validation and Regulatory Standardization, bridging the gap between discovery and clinical trials.
TECHNICAL EXPERTISE (OFFERED SERVICES):
1. Pharma CRMs & Chemistry (Hit-to-Lead):
Certified Reference Materials: Custom synthesis and certification of pharmaceutical impurities and standards to ensure regulatory compliance.
Structural Characterization: Full elucidation using high-end NMR, XRD, and Mass Spectrometry.
2. In Vitro & In Vivo Pre-clinical Validation:
High-Throughput Screening: Cytotoxicity (MTT/SRB), Antiviral (BSL-2/3), and Antibacterial profiling (MIC/Biofilm).
Pharmacokinetics (PK/PD): Bioanalysis via LC-MS/MS for plasma/tissue distribution in rodent models (Oral, IV, IP).
Disease Models: Validated in vivo models for Oncology, Metabolic Syndrome, and Inflammation.
3. Advanced Nano-Formulation:
Nanotechnology: Design and characterization of Liposomes, PLGA/PLA nanoparticles, and Solid Lipid Nanoparticles (SLNs) for targeted drug delivery.
WHY PARTNER WITH NAWAH?
Dual Reach (EU & MENA): With offices in Poland and Egypt, we provide a gateway to diverse biological samples and regional markets while maintaining strict European quality standards.
Regulatory Ready: All workflows are governed by ISO 17025 and GLP-aligned protocols.
Speed: Our centralized Cloud Lab model accelerates TRL advancement by reducing validation timelines by up to 40%.
LOOKING FOR: We are seeking to lead Work Packages in:
ISO 17025 CRO operating in MENA & EU. We offer Pharma CRMs, Pre-clinical Validation, PK/PD & Nano-formulation.
Partner seeks Consortium/Coordinator
DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)